Showing results (51-60 of 555) with videos related to
Sort By:
Pageof 56
Methods in Molecular Medicine|August 2, 2007
Polymorphisms within epithelial receptors: NOD2/CARD15Julia Brenmoehl, Ernst Holler, Gerhard RoglerMedizinische Klinik (Munich, Germany : 1983)|May 11, 2010
[Serious course of a miliary tuberculosis in a 34-year-old patient with ulcerative colitis and HIV infection under concomitant therapy with infliximab]Jonas Zeitz, Milo Huber, Gerhard RoglerJournal of Gastrointestinal and Liver Diseases : JGLD|March 27, 2026
Endoscopic Submucosal Dissection for Colorectal Lesions in a Community-based European Hospital: Experience and Learning CurveThomas Balanis, Gerhard Rogler, Radu TutuianDigestive Diseases (Basel, Switzerland)|February 2, 2017
Anti-Cytokine Strategies beyond Anti-Tumour Necrosis Factor-α Therapy: Pathophysiology and Clinical ImplicationsGerhard Rogler, Luc Biedermann, Michael ScharlAnnals of the New York Academy of Sciences|August 10, 2020
Reconsidering the "protective" hypothesis of Helicobacter pylori infection in eosinophilic esophagitisMichael Doulberis, Jannis Kountouras, Gerhard RoglerInflammatory Intestinal Diseases|September 18, 2018
The Management of Inflammatory Bowel Disease in Elderly: Current Evidence and Future PerspectivesIan Arnott, Gerhard Rogler, Jonas HalfvarsonClinical and Translational Gastroenterology|July 14, 2017
Fistulizing Crohn's DiseaseMichael Scharl, Gerhard Rogler, Luc BiedermannVisceral Medicine|April 8, 2024
Microbiota Therapy in Inflammatory Bowel DiseaseLuc Biedermann, Andrea Kreienbühl, Gerhard RoglerEuropean Journal of Gastroenterology & Hepatology|October 23, 2010
Infliximab for Crohn's disease in the Swiss IBD Cohort Study: clinical management and appropriatenessPascal Juillerat, Valérie Pittet, John-Paul Vader, et al.Inflammatory Bowel Diseases|April 22, 2011
Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel diseaseStephan R Vavricka, Sabrina M Spigaglia, Gerhard Rogler, et al.Pageof 56